NDAOPHTHALMICOINTMENT
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
AVACLYR (acyclovir) by Charter Medical is dna polymerase inhibitors [moa]. Approved for herpes simplex, genital herpes, herpes labialis and 1 more indications. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVACLYR is an ophthalmic ointment formulation of acyclovir, a DNA polymerase inhibitor nucleoside analog approved in March 2019 for treating herpes simplex virus infections including genital herpes, herpes labialis, and herpes zoster. The drug works by inhibiting viral DNA polymerase, preventing viral replication in infected cells. This topical route differentiates it within the acyclovir portfolio for localized ocular and periocular herpes management.
PeakPost-LOE
AVACLYR is at peak lifecycle with moderate competitive pressure (30%), indicating stable team structure and consistent market demand in the specialized ophthalmic antiviral segment.
Mechanism of Action
DNA Polymerase Inhibitors
Pharmacologic Class:
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Indications (4)
Worked on AVACLYR at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.